AccessibilityHelpAbout Us
cbdMD logo

cbdMD(NYSEMKT) YCBD

Market Cap$5.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-31%
1 Month-7%
$0.47
+1.30%
+0.01Today
cbdMD last closing stock price
MetricPriceDate
Last closeUSD 0.462026-09-15
cbdMD stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.93%USD 0.502026-09-08
1 month-7.2%USD 0.502026-08-14
3 month-33.03%USD 0.692026-06-17
Year to date-65.92%USD 1.352025-12-31
1 year-31.46%USD 0.672025-09-15
3 year-95.74%USD 10.802023-09-15
5 year-99.94%USD 712.802021-09-16
Since inception-99.96%USD 1,036.802018-12-21

cbdMD Financials at a Glance

Market Cap

$5.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$20.93M

Net Income (TTM)

-$2.89M

EPS (TTM)

-$0.31

P/E Ratio

-1.49

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$0.47

Volume

48,781

Open

$0.46

Previous Close

$0.47

Daily Range

$0.46 - $0.48

52-Week Range

$0.45 - $2.56

Estimated Earnings Date

Dec 18, 2026

YCBD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About cbdMD

cbdMD makes wellness products using cannabidiol (CBD) from hemp for people and pets. Its products help with sleep, stress, and mobility, offering options like gummies and pet chews. Customers use these for daily routines, such as better sleep or easing pet discomfort.

What’s in the Bottle? cbdMD’s Main Offerings

  • cbdMD (Human CBD Products): Tinctures, gummies, topicals, capsules, and sleep aids for adults. E-commerce sales accounted for 80.4% of FY2024 total net sales.
  • Paw CBD (Pet CBD Products): Veterinarian-formulated tinctures, chews, and topicals for pets; approximately 7.4% of FY2024 sales.
  • ATRx Labs (Functional Mushrooms): Supplements with mushrooms like Lion’s Mane and Reishi for focus and immunity; launched FY2024.
  • Hemp-Derived Beverages: Drink mixers and ready-to-drink cans for relaxation and social use; new in FY2024.
  • cbdMD Therapeutics: Clinical research and product development for new cannabinoid-based wellness solutions.

Growth Spurts and Strategic Moves

  • Launched ATRx Labs mushroom line in GNC and Amazon in FY2024.
  • Entered hemp beverage market with cbdMD Mixer and Herbal Oasis Social Tonics in FY2024.
  • Expanded retail presence with new products in Sprouts and added KeHe as a distributor in FY2024.
  • Grew international sales to 31 countries, focusing on South America and the UK in FY2024.
  • Reduced operating expenses by 36.4% in FY2024 to address industry contraction.

Why cbdMD Stands Out (Without the Hype)

cbdMD relies on direct-to-consumer e-commerce, which made up 80% of sales in FY2024. The company emphasizes product safety, third-party lab testing, and compliance with U.S. hemp laws. It also invests in clinical research to support product claims and adapts quickly to regulatory changes.

Five Things You Need to Know

  • Net sales were $19.5 million in FY2024, down 19% from FY2023.
  • Gross profit margin was 61.6% in FY2024, nearly flat year-over-year.
  • Operating loss improved to $(3.3) million in FY2024 from $(22.5) million in FY2023.
  • Cash and cash equivalents were $2.45 million as of September 30, 2024.

Bottom Line

cbdMD has diversified its product lines and reduced costs to adapt to a challenging market. The company’s focus on research, quality, and new categories shapes its evolving business model.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

42

CEO

T. Ronan Kennedy, MBA

Website

www.cbdmd.com

Headquarters

Charlotte, NC 28273, US

YCBD Financials

Key Financial Metrics (TTM)

Gross Margin

56.48%

Operating Margin

-13.87%

Net Income Margin

-13.80%

Return on Equity

-34.25%

Return on Capital

-0.28%

Return on Assets

-21.97%

Earnings Yield

-67.11%

Dividend Yield

0.00%

Payout Ratio

-41.64%

Stock Overview

Market Cap

$5.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.21M

Volume

48.78K

Avg. Volume

204.42K

Financials (TTM)

Gross Profit

$11.82M

Operating Income

-$2.90M

EBITDA

-$1.62M

Operating Cash Flow

-$443.93M

Capital Expenditure

-$182.88M

Free Cash Flow

-$626.00M

Cash & ST Invst.

$2.12M

Total Debt

$2.21M

cbdMD Performance Analysis

cbdMD annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30USD 35,403,224-20.4%
20232023-09-30USD 24,155,362-31.8%
20242024-09-30USD 19,482,167-19.3%
20252025-09-30USD 19,190,468-1.5%
cbdMD sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-302.5%
Q12025-12-316.3%
Q22026-03-3112.4%
Q32026-06-30-1.5%
cbdMD annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30USD -446.37162.5%
20232023-09-30USD -106.57-76.1%
20242024-09-30USD -14.29-86.6%
20252025-09-30USD -1.09-92.4%
cbdMD sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-3063.7%
Q12025-12-3152.7%
Q22026-03-31-132.7%
Q32026-06-30-31.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$5.55M

+20.6%

Gross Profit

$3.04M

+7.3%

Gross Margin

54.69%

N/A

Market Cap

$5.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$122.74K

N/A

Employees

42

N/A

Net Income

-$1.13M

-25.9%

EBITDA

-$1.13M

-153.0%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$2.12M

+99.9%

Total Debt

$2.21M

+129.8%

Accounts Receivable

$1.75M

+81.2%

Inventory

$3.28M

+17.1%

Long Term Debt

$1.85M

+821.3%

Short Term Debt

$358.27K

-53.0%

Return on Assets

-21.97%

N/A

Return on Invested Capital

-28.84%

N/A

Free Cash Flow

-$460.22M

-65117.4%

Operating Cash Flow

-$442.16M

-62688.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CDIOCardio Diagnostics Holdings, Inc.
$2.00+0.00%
FLGCFlora Growth Corp.
$7.79-32.14%
SBFMSunshine Biopharma, Inc.
$1.03+0.00%
MHUAMeihua International Medical Technologies Co., Ltd.
$7.61-14.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
MEDSDataMEDS Ai
$6.07+274.69%
AALAmerican Airlines Group
$12.70-0.55%
NOKNokia
$10.14+3.05%
INTCIntel
$101.05+4.03%

Questions About YCBD

What is the current price of cbdMD?

cbdMD is trading at $0.47 per share.

What is the 52-week range for cbdMD?

Over the past 52 weeks, cbdMD has traded between $0.45 and $2.56.

How much debt does cbdMD have?

As of the most recent reporting period, cbdMD reported total debt of $2.21M.

How much cash does cbdMD have on hand?

cbdMD reported $2.12M in cash and cash equivalents in its most recent financial results.

What is cbdMD’s dividend yield?

cbdMD does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services